Hence, our comprehensive study provides novel insights into a subgroup of squamous differentiated bladder tumors that hold clues for novel therapeutic regimens and may benefit from FGFR3-targeted therapies. The gene discussed is FGFR3; the disease is urinary bladder neoplasm.